IMT-19

**IMT-19** is an investigational **monoclonal antibody** immuno-oncology program originally developed by **iOmx Therapeutics** for **solid tumors**. Publicly accessible source material on this asset is sparse, but secondary drug intelligence databases describe it as a **T-lymphocyte stimulator**, consistent with an intended **immunostimulatory anticancer** mechanism. Specific molecular target, epitope, route, formulation, and clinical-stage details are not clearly disclosed in the available public sources reviewed; development appears to have remained early, and at least one source lists the program as **discontinued** while another lists it as **preclinical**, so the exact current status is uncertain.